Korsana Biosciences announced a $175 million financing to advance antibody therapeutics engineered to cross the blood‑brain barrier for Alzheimer’s disease. The startup’s preclinical program uses a platform designed to ferry antibodies into the central nervous system; Roche and AbbVie have taken related approaches into the clinic, underscoring competitive validation. The funding should support IND‑enabling studies and expand preclinical pipelines targeting CNS delivery—a persistent bottleneck for antibody and biologic therapies. Korsana’s raise signals continued investor appetite for platform technologies that directly address delivery barriers in neurodegenerative disease.